Experienced in Familial Hypertriglyceridemia

Bipin K. Sethi

Banjara Hills, 
Hyderabad, TG, IN 
Experienced in Familial Hypertriglyceridemia
Banjara Hills, 
Hyderabad, TG, IN 
OverviewLocationsClinical Research

Overview

Bipin Sethi practices in Hyderabad, India. Sethi is rated as an Experienced expert by MediFind in the treatment of Familial Hypertriglyceridemia. Their top areas of expertise are Type 2 Diabetes (T2D), Low Blood Sugar, Diabetic Ketoacidosis, and Type 1 Diabetes (T1D).

Their clinical research consists of co-authoring 49 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Familial Hypertriglyceridemia.

Locations

Banjara Hills, Hyderabad, TG, India

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
An OpenLabel, Multicenter, Non-randomized, ActiveControlled, SingleDose Escalation, Study to Evaluate the Pharmacodynamics,Pharmacokinetics,Safety, and Tolerability of IN-105 Under Fed Conditions In Patients With Type 1 Diabetes Mellitus
An OpenLabel, Multicenter, Non-randomized, ActiveControlled, SingleDose Escalation, Study to Evaluate the Pharmacodynamics,Pharmacokinetics,Safety, and Tolerability of IN-105 Under Fed Conditions In Patients With Type 1 Diabetes Mellitus
Enrollment Status: Terminated
Publish Date: January 23, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 2 Less Clinical Trials

49 Total Publications

Correction: Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial.
Correction: Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial.
Journal: Cardiovascular diabetology. Endocrinology reports
Published: September 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Sethi's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile